This book addresses the most pressing current questions in the
management of urologic malignancies. The rapid advances in imaging and
molecular markers are placed into a clinical context, with explanation
of their effects on prognosis and treatment planning. Similarly,
progress in immunotherapy is carefully examined, focusing in particular
on the role of immune checkpoint inhibitors in both early- and
late-stage urologic malignancies. Looking beyond the improvements in
minimally invasive techniques for urologic cancers, the impacts of care
coordination pathways and enhanced recovery after surgery protocols are
reviewed. Readers will also find enlightening discussion of the decision
algorithm for the treatment of early-stage, high-grade bladder cancer,
taking into account evidence on the most advanced treatment options and
the circumstances in which surgery may need to be expedited. The
penultimate chapter discusses the Cancer Genome Atlas project for
bladder cancer, and the book closes by considering contemporary medical
and surgical management of testicular cancer.